Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 2/20 | 0.75 |
| ▸ | OPRL1 | P41146 | 3/20 | 0.67 |
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.61 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3610068 | 0.99 | OPRM1 (0.73) | OPRM1OPRL1SIGMAR1OPRD1KMT2A | |
| SCHEMBL4872137 | 0.86 | OPRM1 (0.70) | OPRM1OPRL1SIGMAR1OPRD1KMT2A | |
| SCHEMBL476404 | 0.86 | OPRM1 (1.00) | OPRM1OPRL1SIGMAR1OPRD1 | |
| Hydrochloric Acid SCHEMBL8355555 | 0.85 | OPRM1 (0.68) | OPRM1OPRL1SIGMAR1KMT2A | |
| Hydrochloric Acid SCHEMBL2473959 | 0.85 | OPRM1 (0.97) | OPRM1OPRL1SIGMAR1OPRD1 | |
| SCHEMBL8350406 | 0.80 | OPRM1 (0.81) | OPRM1OPRL1SIGMAR1OPRD1 | |
| SCHEMBL5480849 | 0.80 | OPRM1 (0.60) | OPRM1OPRL1SIGMAR1KMT2A | |
| SCHEMBL3895012 | 0.79 | OPRM1 (0.83) | OPRM1OPRL1SIGMAR1OPRD1 | |
| SCHEMBL8267914 | 0.78 | SIGMAR1 (0.62) | SIGMAR1KMT2A | |
| SCHEMBL6216980 | 0.78 | SIGMAR1 (0.49) | OPRM1OPRL1SIGMAR1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7704996-B2 | Compounds and compositions useful as cathepsin S inhibitors | NOVARTIS AG (CH) | 2010-04-27 | — | — | US | disclosed |
| CN-101671310-A | Compounds and compositions useful as cathepsin s inhibitors | NOVARTIS AG | 2010-03-17 | — | — | CN | disclosed |
| US-20090048230-A1 | COMPOUNDS AND COMPOSITIONS USEFUL AS CATHEPSIN S INHIBITORS | NOVARTIS AG (CH) | 2009-02-19 | — | — | US | disclosed |
| CN-101035768-A | Compounds and compositions as cathepsin S inhibitors | NOVARTIS AG (CH) | 2007-09-12 | — | — | CN | disclosed |
| EP-1781623-A1 | COMPOUNDS AND COMPOSITIONS USEFUL AS CATHEPSIN S INHIBITORS | Novartis AG (CH) | 2007-05-09 | — | — | EP | disclosed |
| WO-2006018284-A1 | COMPOUNDS AND COMPOSITIONS USEFUL AS CATHEPSIN S INHIBITORS | NOVARTIS AG (CH) | 2006-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048230-A1 | COMPOUNDS AND COMPOSITIONS USEFUL AS CATHEPSIN S INHIBITORS | CTSS, CTSZ, CTSF | OPRM1 2515/4885OPRL1 3275/4885SIGMAR1 4070/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.